Tag: Bristol-Myers Squibb
Bristol Myers Squibb Acquires Orum Therapeutics’ ORM-6151 Program
Bristol Myers Squibb (BMS) has acquired Orum Therapeutics’ ORM-6151 program, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes.[1]
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...
FDA Accepts Investigational New Drug Application for CTLA-4 Probody Therapeutic
Bristol-Myers Squibb has received acceptance of the Investigational New Drug application (IND) from the U.S. Food and Drug Administration (FDA) for a CTLA-4-directed Probody™...
AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...
A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...
Nivolumab and DS-8201 to be Evaluated in HER2-Expressing Breast and Bladder...
Bristol-Myers Squibb and Daiichi Sankyo have agreed to collaborate in a clinical trial to evaluate the combination of Bristol-Myers Squibb’s immunotherapy nivolumab (Opdivo®) and...
Seattle Genetics buys Bristol-Myers Squibb’s Pharmaceutical Manufacturing Facility in Bothell, Washington
Seattle Genetics has agreed to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in the North Creek area of Bothell, WA, a short drive from Seattle....
Drugs and Drug Hunters
All products of the creative process are a reflection of the individual makeup of the inventors. A painting by Mark Rothko looks like a...
Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...
The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with nivolumab (Opdivo; Bristol-Myers Squibb...
CytomX Therapeutics and Bristol-Myers Squibb Continue Collaboration
CytomX Therapeutics, an oncology-focused biopharmaceutical company based in South San Francisco developing investigational Probody™ therapeutics for the treatment of cancer, earlier today announced that...
